Baker Avenue Asset Management LP lessened its position in SPDR S&P Biotech ETF (NYSEARCA:XBI) by 12.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 21,508 shares of the exchange traded fund’s stock after selling 3,067 shares during the period. Baker Avenue Asset Management LP’s holdings in SPDR S&P Biotech ETF were worth $1,543,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of XBI. Cranbrook Wealth Management LLC bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter worth approximately $26,000. Truewealth LLC bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter worth approximately $29,000. Quattro Financial Advisors LLC lifted its stake in shares of SPDR S&P Biotech ETF by 49.6% in the fourth quarter. Quattro Financial Advisors LLC now owns 374 shares of the exchange traded fund’s stock worth $31,000 after buying an additional 124 shares in the last quarter. Lehman & Derafelo Financial Resources LLC bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter worth approximately $32,000. Finally, Essex Savings Bank bought a new position in shares of SPDR S&P Biotech ETF in the fourth quarter worth approximately $120,000.

Shares of NYSEARCA XBI opened at $90.33 on Thursday. SPDR S&P Biotech ETF has a 52-week low of $64.38 and a 52-week high of $101.55.

COPYRIGHT VIOLATION NOTICE: “Baker Avenue Asset Management LP Has $1.54 Million Stake in SPDR S&P Biotech ETF (XBI)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2019/03/21/baker-avenue-asset-management-lp-has-1-54-million-stake-in-spdr-sp-biotech-etf-xbi.html.

About SPDR S&P Biotech ETF

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Further Reading: Net Margin – Understanding the Different Kinds of Profit

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.